Evidence map›Paper›PMID 31865813›Full record

ReviewExpert opinion on therapeutic patents2020

A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).

Sida Shen, Alan P Kozikowski

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on therapeutic patents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Intepirdine Derivatives Possessing Dual 5HT6 Antagonism / HDAC6 Inhibitory Activity.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Design, synthesis, biological andBiomedical reports · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sida ShenDepartments of Chemistry, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics, Northwestern University, Evanston, IL, USA.ORCID https://orcid.org/0000-0002-0295-2545
Alan P KozikowskiStarWise Therapeutics LLC, Chicago, IL, USA.ORCID https://orcid.org/0000-0003-4795-5368
Northwestern University · US

Funding

Optimization of HDAC6 Inhibitors in the Treatment of CMTR01NS079183 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KOZIKOWSKI, ALAN P., VAN DEN BOSCH, LUDO · 2013 to 2017
$1.9M
Study of the New HDAC6i SW-100 as a Treatment for Alzheimer’s Disease and Other TauopathiesR41AG058283 · NIA · STARWISE THERAPEUTICS, LLC · PI GORDON, MARCIA N, KOZIKOWSKI, ALAN P. · 2017 to 2017
$393k
AN HDAC6 APPROACH TO RETT SYNDROMER43HD093464 · NICHD · STARWISE THERAPEUTICS, LLC · PI KOZIKOWSKI, ALAN P. · 2017 to 2017
$300k
NIA NIH HHS R41 AG058283NICHD NIH HHS R43 HD093464NINDS NIH HHS R01 NS079183
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsDrug DevelopmentHistone Deacetylase 6Histone Deacetylase InhibitorsHumansNeurodegenerative DiseasesPatents as TopicHDAC6 protein, humanHistone Deacetylase 6Histone Deacetylase Inhibitorsarylhydroxamatemitochondria transportmutagenicityoxadiazoleΑ-tubulin acetylation

Identifiers

PMID31865813
PMCPMC6950832
OpenAlexW2995880656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.